InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,424.38
(
-0.18%
)
US TECH 100
18,428.80
(
-0.40%
)
Dow Jones
39,819.45
(
0.14%
)
Brent Oil
80.19
(
-0.51%
)
Bitcoin
59,136.15
(
-2.45%
)
Post# of 252883
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120268
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Friday, 09/23/2016 9:13:23 AM

Friday, September 23, 2016 9:13:23 AM

Post# of 252883
ABBV/ENTA—First 8-week V-Pak* data—>98% SVR12 in treatment-naïve GT1b patients:

http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-newsArticle&ID=2205562

160 of 163 patients (98.2%) enrolled in the open-label phase-3b GARNET study attained SVR12.

V-Pak does not currently have an approved 8-week treatment option for a subset of GT1 patients, as GILD's Harvoni does.

*Viekira Pak is called Viekirax + Exviera in Europe.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up